Your browser doesn't support javascript.
loading
Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
Lupia, Michela; Melocchi, Valentina; Bizzaro, Francesca; Lo Riso, Pietro; Dama, Elisa; Baronio, Micol; Ranghiero, Alberto; Barberis, Massimo; Bernard, Loris; Bertalot, Giovanni; Giavazzi, Raffaella; Testa, Giuseppe; Bianchi, Fabrizio; Cavallaro, Ugo.
Afiliación
  • Lupia M; Unit of Gynaecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy.
  • Melocchi V; Unit of Cancer Biomarkers, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Bizzaro F; Laboratory of Tumor Metastasis Therapeutics, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.
  • Lo Riso P; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Dama E; Unit of Cancer Biomarkers, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Baronio M; Unit of Gynaecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy.
  • Ranghiero A; Pathology Unit, European Institute of Oncology IRCCS, Milan, Italy.
  • Barberis M; Pathology Unit, European Institute of Oncology IRCCS, Milan, Italy.
  • Bernard L; Clinical Genomics Lab, European Institute of Oncology IRCCS, Milan, Italy.
  • Bertalot G; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Giavazzi R; Laboratory of Tumor Metastasis Therapeutics, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.
  • Testa G; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Bianchi F; Department of Oncology and Haemato-Oncology, University of Milan, Italy.
  • Cavallaro U; Unit of Cancer Biomarkers, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Int J Cancer ; 151(2): 240-254, 2022 07 15.
Article en En | MEDLINE | ID: mdl-35218560
ABSTRACT
High-grade serous ovarian carcinoma (HGSOC) is a highly aggressive and intractable neoplasm, mainly because of its rapid dissemination into the abdominal cavity, a process that is favored by tumor-associated peritoneal ascites. The precise molecular alterations involved in HGSOC onset and progression remain largely unknown due to the high biological and genetic heterogeneity of this tumor. We established a set of different tumor samples (termed the As11-set) derived from a single HGSOC patient, consisting of peritoneal ascites, primary tumor cells, ovarian cancer stem cells (OCSC) and serially propagated tumor xenografts. The As11-set was subjected to an integrated RNA-seq and DNA-seq analysis which unveiled molecular alterations that marked the different types of samples. Our profiling strategy yielded a panel of signatures relevant in HGSOC and in OCSC biology. When such signatures were used to interrogate the TCGA dataset from HGSOC patients, they exhibited prognostic and predictive power. The molecular alterations also identified potential vulnerabilities associated with OCSC, which were then tested functionally in stemness-related assays. As a proof of concept, we defined PI3K signaling as a novel druggable target in OCSC.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Int J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Int J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Italia